Rep. Josh Gottheimer Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on February 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on January 24th.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 1/31/2025.
• Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Mastercard (NYSE:MA) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/30/2025.
• Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 1/30/2025.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $663.86 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73. The company has a market capitalization of $72.95 billion, a PE ratio of 17.34, a P/E/G ratio of 2.38 and a beta of 0.08. The company has a 50 day moving average price of $710.88 and a 200-day moving average price of $901.80. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period last year, the business posted $11.86 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.53%.

Analysts Set New Price Targets

REGN has been the subject of several recent research reports. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. TD Cowen cut their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Finally, Barclays cut their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Rakuten Securities Inc. increased its holdings in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the period. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $28,000. Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $36,000. Finally, Crowley Wealth Management Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $36,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.